Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Operating Grant: SARS-CoV-2 variants supplement stream 1

McMaster University

$50,000.00

COVID-19 Variant Supplement - Targeting genetic and chemical vulnerabilities of novel coronavirus SARS-CoV-2

FY 2020-21

Summary
The recent outbreak of the SARS-CoV-2 coronavirus in China and its continued international spread threatens to become a global pandemic. Although coronaviruses generally cause mild respiratory infections in humans, over the past 18 years, three animal-derived coronaviruses have emerged that cause much more severe disease: SARS-CoV, MERS-CoV, and the current SARS-CoV-2. Each of these emergent viruses cause substantially higher death rates than common coronavirus infections; the current estimate of the death rate due to COVID-19 syndrome caused by SARS-CoV-2 infection is ~2.5%. The main challenge in addressing these new coronavirus-associated outbreaks is a lack of suitable therapeutics to treat active disease (i.e., anti-viral drugs) or to prevent disease (i.e., appropriate vaccines). We propose to apply genomics-based tools and drug-screening platforms to rapidly pinpoint new targets for SARS-CoV-2 anti-viral agents and to identify candidate therapeutic compounds. Our team has deep expertise in anti-infective drug discovery, the application of genomics in identifying drug targets, and in the biology and biochemistry of RNA viruses such as SARS-CoV-2. Our project will identify new therapeutic strategies that may help to treat COVID-19 patients. These strategies will also help mitigate newly emergent coronavirus-associated diseases that will undoubtedly continue to cause outbreaks in the future.
Program
Operating Grant: SARS-CoV-2 variants supplement stream 1
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
443283
Name
Wright Gerard D
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Special Cases
Projecttitle
COVID-19 Variant Supplement - Targeting genetic and chemical vulnerabilities of novel coronavirus SARS-CoV-2
Programtype2
Operating Grants
Orgnameinp2
McMaster University
Cihramount2
$50,000
Cihrequipment2
$0
Programname2
Operating Grant: SARS-CoV-2 variants supplement stream 1
Keyworddelim
Anti-Viral Discovery; Genomics; Therapeutics
Abstract
The recent outbreak of the SARS-CoV-2 coronavirus in China and its continued international spread threatens to become a global pandemic. Although coronaviruses generally cause mild respiratory infections in humans, over the past 18 years, three animal-derived coronaviruses have emerged that cause much more severe disease: SARS-CoV, MERS-CoV, and the current SARS-CoV-2. Each of these emergent viruses cause substantially higher death rates than common coronavirus infections; the current estimate of the death rate due to COVID-19 syndrome caused by SARS-CoV-2 infection is ~2.5%. The main challenge in addressing these new coronavirus-associated outbreaks is a lack of suitable therapeutics to treat active disease (i.e., anti-viral drugs) or to prevent disease (i.e., appropriate vaccines). We propose to apply genomics-based tools and drug-screening platforms to rapidly pinpoint new targets for SARS-CoV-2 anti-viral agents and to identify candidate therapeutic compounds. Our team has deep expertise in anti-infective drug discovery, the application of genomics in identifying drug targets, and in the biology and biochemistry of RNA viruses such as SARS-CoV-2. Our project will identify new therapeutic strategies that may help to treat COVID-19 patients. These strategies will also help mitigate newly emergent coronavirus-associated diseases that will undoubtedly continue to cause outbreaks in the future.
Competitiondate
202102
Approvedterm2
1 yr 0 mth
Pinamesdelim
Wright, Gerard D; Miller, Matthew S; Tyers, Michael D
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $50,000~ $0~